Related Experiment Video

Updated: Aug 20, 2026

Monitoring On-Target Signaling Responses in Larval Zebrafish - Z-REX Unmasks Precise Mechanisms of Electrophilic Drugs and Metabolites
05:28

Monitoring On-Target Signaling Responses in Larval Zebrafish - Z-REX Unmasks Precise Mechanisms of Electrophilic Drugs and Metabolites

Published on: June 2, 2023

Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene

James R Rigas1, Konstantin H Dragnev

  • 1Comprehensive Thoracic Oncology Program, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, New Hampshire 03756, USA. james.r.rigas@dartmouth.edu

The Oncologist
|January 6, 2005
PubMed

Insights

Bexarotene, a novel rexinoid, shows promise in treating non-small cell lung cancer. Clinical trials indicate it is safe, well-tolerated, and improves survival when combined with chemotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Non-small cell lung cancer (NSCLC) remains a leading cause of cancer death globally, necessitating novel therapeutic strategies.
  • Retinoids regulate cell processes and are explored for cancer therapy, but retinoic acid receptor agonists cause significant side effects.
  • Rexionoids, synthetic agents targeting retinoid X receptors, offer a new therapeutic avenue with potentially improved safety profiles.

Purpose of the Study:

  • To review the rationale for using rexinoids in cancer treatment.
  • To discuss the clinical profile of bexarotene, a synthetic rexinoid, for non-small cell lung cancer therapy.

Main Methods:

  • Review of existing literature on rexinoids and bexarotene.
  • Analysis of Phase I and II clinical trial data for bexarotene in NSCLC patients.
  • Comparison of bexarotene's safety and efficacy with traditional retinoids and chemotherapy.

Main Results:

  • Bexarotene is safe and well-tolerated in NSCLC patients, alone or with chemotherapy.
  • Adverse events with bexarotene are manageable and less severe than with retinoic acid receptor-specific retinoids.
  • Bexarotene combined with chemotherapy shows encouraging median survival in advanced NSCLC.

Conclusions:

  • Rexionoids, exemplified by bexarotene, represent a promising targeted therapy for malignancies.
  • Bexarotene demonstrates a favorable safety and efficacy profile in non-small cell lung cancer treatment.
  • Further Phase III trials are ongoing to establish bexarotene's definitive role in NSCLC therapy.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...